Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Subtypes of glioblastoma multiforme (GBM) based on genetic and molecular alterations are thought to cause alterations in anatomic MRI owing to downstream biological changes, such as edema production, blood-brain barrier breakdown, and necrosis. The purpose of the current study was to identify a potential relationship between imaging features and the mesenchymal (MES) GBM subtype, which has the worst patient prognosis. METHODS: MRIs from 46 patients with histologically confirmed GBM were retrospectively analyzed. The volume of contrast enhancement, regions of central necrosis, and hyperintensity of T2/fluid attenuated inversion recovery (FLAIR) were measured. Additionally, the ratio of T2/FLAIR hyperintense volume to the volume of contrast enhancement and necrosis was calculated. RESULTS: The volume of contrast enhancement, volume of central necrosis, combined volume of contrast enhancement and central necrosis, and the ratio of T2/FLAIR to contrast enhancement and necrosis were significantly different in MES compared with non-MES GBM (Mann-Whitney, P < .05). Receiver-operator characteristics indicated that these 4 metrics were all significant predictors of the MES phenotype. The volume ratio of T2 hyperintensity to contrast enhancement and central necrosis was significantly lower in MES vs non-MES GBM (P < .0001), was a significant predictor of the MES phenotype (area under the curve = 0.93, P < .001), and could be used to stratify short- and long-term overall survival (log-rank, P = .0064 using cutoff of 3.0). These trends were also present when excluding isocitrate dehydrogenase 1 mutant tumors and incorporating covariates such as age and KPS score. CONCLUSIONS: Results suggest that volume ratio may be a simple, cost-effective, and noninvasive biomarker for quickly identifying MES GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · cited 1×
“According to a recent study by The Cancer Genome Atlas Research Network, GBM should not be considered a single disease but rather should be categorized by molecular subtypes, each with a different sensitivity to therapy.(2) For example, patients whose tumors have a signature enriched in genes associated with neural de…”
MethodDecoding global gene expression programs in liver cancer by noninvasive imaging
Segal, E., Sirlin, C. B., Ooi, C., Adler, A. S., Gollub, J., Chen, X., Chan, B. K., Matcuk, G. R., Barry, C. T., Chang, H. Y., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1306 · Cited by 629
Identification of noninvasive imaging surrogates for brain tumor gene-expression modules
Diehn, M., Nardini, C., Wang, D. S., McGovern, S., Jayaraman, M., Liang, Y., Aldape, K., Cha, S., & Kuo, M. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801279105 · Cited by 440
Kuo, M. D., Gollub, J., Sirlin, C. B., Ooi, C., & Chen, X. (2007) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2007.04.031 · Cited by 168
Cited by
Applications and limitations of radiomics
Yip, S. S. F., & Aerts, H. J. W. L. (2016) · Physics in Medicine and Biology · doi:10.1088/0031-9155/61/13/r150 · Cited by 1,210
Mechanisms of immunotherapy resistance: lessons from glioblastoma
Jackson, C. M., Choi, J., & Lim, M. (2019) · Nature Immunology · doi:10.1038/s41590-019-0433-y · Cited by 751
The Potential of Radiomic-Based Phenotyping in Precision Medicine: A Review
Aerts, H. J. W. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2631 · Cited by 669
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
Ellingson, B. M., Wen, P. Y., & Cloughesy, T. F. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0507-6 · Cited by 476
Self-citationNeutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression
Yee, P. P., Wei, Y., Kim, S.-Y., Lu, T., Chih, S. Y., Lawson, C., Tang, M., Liu, Z., Anderson, B., Thamburaj, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19193-y · Cited by 412
Metadata
- Authors
- Naeini, K. M., Pope, W. B., Cloughesy, T. F., Harris, R. J., Lai, A., Eskin, A., Chowdhury, R., Phillips, H. S., Nghiemphu, P. L., Behbahanian, Y., & Ellingson, B. M.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02-26
- Volume
- 15
- Issue
- 5
- Pages
- 626-634
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2140237552
- Cited by
- 101
- References
- 4
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.